Spero Cataland

403 total citations
9 papers, 67 citations indexed

About

Spero Cataland is a scholar working on Immunology, Nephrology and Physiology. According to data from OpenAlex, Spero Cataland has authored 9 papers receiving a total of 67 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Nephrology and 4 papers in Physiology. Recurrent topics in Spero Cataland's work include Complement system in diseases (8 papers), Renal Diseases and Glomerulopathies (5 papers) and Adenosine and Purinergic Signaling (4 papers). Spero Cataland is often cited by papers focused on Complement system in diseases (8 papers), Renal Diseases and Glomerulopathies (5 papers) and Adenosine and Purinergic Signaling (4 papers). Spero Cataland collaborates with scholars based in United States, United Kingdom and Spain. Spero Cataland's co-authors include Éric Rondeau, Ioannis Tomazos, Katherine Garlo, Gema Ariceta, Stephan Ortiz, Marie Scully, Neil Sheerin, Gin‐Fu Chen, Bradley P. Dixon and Kevin Deighton and has published in prestigious journals such as Blood, Nephrology Dialysis Transplantation and Clinical Nephrology.

In The Last Decade

Spero Cataland

8 papers receiving 64 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Spero Cataland United States	6	59	51	26	11	6	9	67
Mercedes Cao Spain	4	54 0.9×	42 0.8×	7 0.3×	28 2.5×	3 0.5×	5	61
Merranda Logan United States	2	27 0.5×	17 0.3×	3 0.1×	3 0.3×	13 2.2×	4	34
Pilar Martinez‐Barranco Spain	3	12 0.2×	12 0.2×	3 0.1×	4 0.4×	2 0.3×	4	31
N. Sheerin United Kingdom	1	22 0.4×	29 0.6×	1 0.0×	3 0.3×	4 0.7×	2	40
Nima Tanha Denmark	4	34 0.6×	16 0.3×		3 0.3×		5	40
Jillian K. Warejko United States	3	7 0.1×	29 0.6×	1 0.0×	3 0.3×	11 1.8×	6	44
Fayna González Spain	2	11 0.2×	12 0.2×		2 0.2×	5 0.8×	4	23
Véronique Hentgen France	1	25 0.4×	8 0.2×		5 0.5×		2	53
María H Esteva-Spinetti Chile	2	18 0.3×	7 0.1×		10 0.9×		4	50
Vuddidhej Ophascharoensuk Thailand	3	12 0.2×	21 0.4×		1 0.1×	6 1.0×	4	40

Countries citing papers authored by Spero Cataland

Since Specialization

Citations

This map shows the geographic impact of Spero Cataland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Spero Cataland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Spero Cataland more than expected).

Fields of papers citing papers by Spero Cataland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Spero Cataland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Spero Cataland. The network helps show where Spero Cataland may publish in the future.

Co-authorship network of co-authors of Spero Cataland

This figure shows the co-authorship network connecting the top 25 collaborators of Spero Cataland. A scholar is included among the top collaborators of Spero Cataland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Spero Cataland. Spero Cataland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Dixon, Bradley P., David Kavanagh, Brigitte Adams, et al.. (2024). Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials. Kidney Medicine. 6(8). 100855–100855. 8 indexed citations

Al‐Samkari, Hanny, Vickie McDonald, Monica Carpenedo, et al.. (2024). Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT). Blood. 144(Supplement 1). 2570.1–2570.1.

Mauch, Teri Jo, Spero Cataland, Shruti Chaturvedi, et al.. (2023). Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. Journal of Comparative Effectiveness Research. 12(9). e230036–e230036. 5 indexed citations

Tomazos, Ioannis, Anthony J. Hatswell, Spero Cataland, et al.. (2021). Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data. Clinical Nephrology. 97(5). 261–272. 17 indexed citations

Dixon, Bradley P., Brigitte Adams, David Kavanagh, et al.. (2021). Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies. Blood. 138(Supplement 1). 769–769. 2 indexed citations

Greenbaum, Larry A., Christoph Licht, Vasileios S. Nikolaou, et al.. (2020). Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry. Kidney International Reports. 5(8). 1161–1171. 11 indexed citations

Barbour, Thomas, Marie Scully, Gema Ariceta, et al.. (2020). SO054ONE-YEAR EFFICACY AND SAFETY OF THE LONG ACTING C5 INHIBITOR RAVULIZUMAB FOR THE TREATMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) IN ADULTS. Nephrology Dialysis Transplantation. 35(Supplement_3). 2 indexed citations

Cataland, Spero, Gema Ariceta, Peter Chen, et al.. (2019). Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab. Blood. 134(Supplement_1). 1099–1099. 14 indexed citations

Fakhouri, Fádi, Maryvonne Hourmant, Josep M. Campistol, et al.. (2013). Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function in Adult Atypical Hemolytic Uremic Syndrome (aHUS) Patients (Pts). Open Repository and Bibliography (University of Liège). 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact